578 related articles for article (PubMed ID: 30031494)
1. Systemic Juvenile Idiopathic Arthritis.
Lee JJY; Schneider R
Pediatr Clin North Am; 2018 Aug; 65(4):691-709. PubMed ID: 30031494
[TBL] [Abstract][Full Text] [Related]
2. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
3. Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome.
Wagner-Weiner L
Pediatr Ann; 2015 Jun; 44(6):e142-7. PubMed ID: 26114369
[TBL] [Abstract][Full Text] [Related]
4. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.
Janow G; Schanberg LE; Setoguchi S; Hasselblad V; Mellins ED; Schneider R; Kimura Y;
J Rheumatol; 2016 Sep; 43(9):1755-62. PubMed ID: 27307527
[TBL] [Abstract][Full Text] [Related]
5. Macrophage activation syndrome in an inadequately treated patient with systemic onset juvenile idiopathic arthritis.
Juneja M; Jain R; Mishra D
Kathmandu Univ Med J (KUMJ); 2009; 7(28):411-3. PubMed ID: 20502084
[TBL] [Abstract][Full Text] [Related]
6. Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.
Kumar S
Indian J Pediatr; 2016 Apr; 83(4):322-7. PubMed ID: 26916892
[TBL] [Abstract][Full Text] [Related]
7. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.
Hinze CH; Holzinger D; Lainka E; Haas JP; Speth F; Kallinich T; Rieber N; Hufnagel M; Jansson AF; Hedrich C; Winowski H; Berger T; Foeldvari I; Ganser G; Hospach A; Huppertz HI; Mönkemöller K; Neudorf U; Weißbarth-Riedel E; Wittkowski H; Horneff G; Foell D;
Pediatr Rheumatol Online J; 2018 Jan; 16(1):7. PubMed ID: 29357887
[TBL] [Abstract][Full Text] [Related]
8. Sustained hyperferritinemia in a child with macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis - perforinopathy: case based review.
Çakan M; Aktay-Ayaz N; Gemici H; Annayev A; Çıtak A; Akçay A; Öztürk G
Turk J Pediatr; 2018; 60(5):598-603. PubMed ID: 30968645
[TBL] [Abstract][Full Text] [Related]
9. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O
Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940
[TBL] [Abstract][Full Text] [Related]
10. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
11. Systemic-onset juvenile idiopathic arthritis.
Cimaz R
Autoimmun Rev; 2016 Sep; 15(9):931-4. PubMed ID: 27392503
[TBL] [Abstract][Full Text] [Related]
12. Anakinra and hepatotoxicity in pediatric rheumatology: a case series.
Martins FR; Azevedo AC; Ganhão S; Aguiar F; Rodrigues M; Brito I
Pediatr Rheumatol Online J; 2023 Oct; 21(1):112. PubMed ID: 37803456
[TBL] [Abstract][Full Text] [Related]
13. Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020: A Nationwide Retrospective Study.
Lukjanoviča K; Šlēziņa I; Dāvidsone Z; Šantere R; Budarina K; Staņēviča V
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109756
[No Abstract] [Full Text] [Related]
14. Glucocorticoids in the management of systemic juvenile idiopathic arthritis.
Vannucci G; Cantarini L; Giani T; Marrani E; Moretti D; Pagnini I; Simonini G; Cimaz R
Paediatr Drugs; 2013 Oct; 15(5):343-9. PubMed ID: 23813411
[TBL] [Abstract][Full Text] [Related]
15. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
Woerner A; von Scheven-Gête A; Cimaz R; Hofer M
Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554
[TBL] [Abstract][Full Text] [Related]
16. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
[TBL] [Abstract][Full Text] [Related]
17. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.
Ambler WG; Nanda K; Onel KB; Shenoi S
Ann Med; 2022 Dec; 54(1):1839-1850. PubMed ID: 35786149
[TBL] [Abstract][Full Text] [Related]
18. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
19. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
[TBL] [Abstract][Full Text] [Related]
20. Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Lu M; Teng L; Xu Y; Xu X
Pediatr Rheumatol Online J; 2023 Oct; 21(1):115. PubMed ID: 37828529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
